Locations:
SearchHow one hematologist learned to use and value it
Using Twitter was not his idea. But after being inspired by peers who were live-tweeting at the 2014 American Society of Hematology Annual Meeting, Cleveland Clinic hematologist Aaron Gerds, MD, has learned that “Twitter isn’t just for millennials.”
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Since then, he’s discovered how Twitter can help him save time in keeping up with the latest developments in his specialty, myeloproliferative neoplasms (MPN). (He follows hematologists, patients and advocacy groups that tweet with the hashtag #MPNSM.) And he’s opened a new line of communication with patients who follow him @AaronGerds.
He shares his perspectives — including tips for physicians nervous about signing up for a Twitter account — in ASH Clinical News.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients